Miladys Palau Collazo
Pediatric Endocrinology · Port St Lucie, FLNPI 1063671212
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $34,931 of the $53,703 with a category attached, or 65.0%. 36 manufacturers reported payments, led by AstraZeneca at 40.2% of the total. Reporting peaked in 2023 at $15,318 and has fallen 92.2% since, to $1,194 in 2025. Among pediatric endocrinology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 328 payments — averaging $163.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$22K
- AbbVie$12K
- Medtronic$10K
- Zealand Pharma US, Inc.$5K
- Ascendis Pharma Endocrinology Inc$788
- Novo Nordisk$583
- plus $3K from 30 others
What the payments were for
- Consulting fees$7,65014%
- Speaking & faculty fees$34,93165%
- Travel & lodging$4,1528%
- Food & beverage$6,79313%
- Education$1770%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 37 | $21,581 |
| AbbVie | 33 | $12,157 |
| Medtronic(2 entities) | 27 | $9,783 |
| Zealand Pharma US, Inc. | 23 | $5,315 |
| Ascendis Pharma Endocrinology Inc | 25 | $788 |
| Novo Nordisk | 28 | $583 |
| Insulet Corporation | 20 | $441 |
| Soleno Therapeutics, Inc. | 9 | $297 |
| Sanofi-aventis U.S. LLC | 8 | $286 |
| Xeris Pharmaceuticals, Inc. | 14 | $272 |
| Tolmar Pharmaceuticals, Inc. | 16 | $250 |
| Azurity Pharmaceuticals, Inc. | 12 | $248 |
| BETA Bionics, Inc. | 1 | $162 |
| Lilly USA, LLC | 8 | $155 |
| Tandem Diabetes Care, Inc. | 8 | $151 |
| Dexcom, Inc. | 7 | $122 |
| Tolmar, Inc. | 6 | $111 |
| Abbott | 5 | $102 |
| Amphastar Pharmaceuticals, Inc. | 4 | $89 |
| Arbor Pharmaceuticals, Inc. | 5 | $85 |
| Neurocrine Biosciences, Inc. | 3 | $82 |
| Pfizer | 3 | $71 |
| Ultragenyx Pharmaceutical Inc. | 2 | $70 |
| Eton Pharmaceuticals, Inc. | 3 | $65 |
| Sequel Med Tech, LLC | 2 | $57 |
| Kyowa Kirin, Inc. | 3 | $54 |
| Endo Pharmaceuticals Inc. | 3 | $53 |
| Mannkind Corporation | 2 | $48 |
| Biomarin Pharmaceutical Inc. | 2 | $43 |
| Sandoz | 1 | $32 |
| Intuity Medical Inc | 2 | $31 |
| Ferring Pharmaceuticals Inc. | 2 | $29 |
| Alnylam Pharmaceuticals Inc. | 1 | $25 |
| Amryt Pharma Holdings Ltd | 1 | $21 |
| IBSA Pharma Inc. | 1 | $21 |
| Companion Medical, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Lupron Depot$11,775
- ZEGALOGUE$4,928
- Strensiq$4,230
- INPEN SMART INSULIN DELIVERY SYSTEM$1,375
- Minimed 670G System$975
- iLet Bionic Pancreas$486
- SKYTROFA$232
- TZIELD$128
How this compares
$53,703 in reported general payments places this provider in the 90th percentile of 102 pediatric endocrinology providers in Florida.
Other pediatric endocrinology in Port St Lucie
- Joshua YangOrlando$846K
- Henry RodriguezTampa$211K
- Dorothy ShulmanTampa$104K
- Michael HallerGainesville$102K
- Alejandro DiazMiami$101K
- Samuel FreedmanPembroke Pines$71K
- Jennifer MillerGainesville$57K
- Laura JacobsenGainesville$36K
- Matthew BensonOrlando$32K
- Konda ReddyWinter Park$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.